PodParley PodParley
PodParley
Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses episode artwork

EPISODE · Apr 22, 2025 · 40 MIN

Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses

from The Studio at Kendall Square · host BiotechTV

Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, and describes how Zola builds off of that. He explains the importance of combining agonists to TLR9 to TLR7 and TLR8, and also describes the virtual set-up that the company has today.

Episode metadata supplied by the publisher feed · Published Apr 22, 2025

Embed this episode

Ready to play

Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses

0:00 40:48

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Studio at Kendall Square?

This episode is 40 minutes long.

When was this The Studio at Kendall Square episode published?

This episode was published on April 22, 2025.

Can I download this The Studio at Kendall Square episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!